a year ago
SRPT
AnalystsGil BlumGil Blum's Stock Forecasts
AnalystsGil Blum
Sectors:
Industries:
Analyst Ranking
Top 4%
#157 out of 5186 analysts
Average Return
+11.86%
Win Rate
39%177 out of 455
Risk vs Reward
Poor
Good
Gil Blum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Celcuity IncCELC | +1,102.60% | $9.23 | $111.00 | 2025-04-10 - 2026-02-03 | Buy |
Celcuity IncCELC | +1,094.83% | $9.29 | $111.00 | 2025-03-31 - 2026-02-03 | Buy |
Celcuity IncCELC | +955.13% | $10.52 | $111.00 | 2025-05-14 - 2026-02-03 | Buy |
Celcuity IncCELC | +781.65% | $12.59 | $111.00 | 2025-02-05 - 2026-02-03 | Buy |
Celcuity IncCELC | +731.46% | $13.35 | $111.00 | 2025-06-29 - 2026-02-03 | Buy |
Gil Blum Analyst Color
Get additional color on Gil Blum's coverage of popular stocks
2 years ago
AUTL
2 years ago
AUTL
Gil Blum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Nurix Therapeutics IncNRIX | 29 | Buy | $26.00 | +54.85% | Reiterates | 6 days ago |
Solid Biosciences IncSLDB | 2 | Buy | $16.00 | +144.65% | Reiterates | 21 days ago |
Mereo Biopharma Group PLCMREO | 21 | Buy | $3.00 | +612.59% | Maintains | 22 days ago |
Autolus Therapeutics PLCAUTL | 34 | Buy | $10.00 | +624.64% | Maintains | 23 days ago |
Cartesian Therapeutics IncRNAC | 24 | Buy | $42.00 | +506.06% | Maintains | a month ago |
Crispr Therapeutics AgCRSP | 27 | Buy | $80.00 | +53.85% | Reiterates | a month ago |
Absci CorpABSI | 7 | Buy | $7.00 | +126.54% | Reiterates | 2 months ago |
Arcellx IncACLX | 23 | Buy | $105.00 | +51.17% | Reiterates | 2 months ago |
Geron CorpGERN | 23 | Buy | $4.00 | +164.90% | Maintains | 3 months ago |
Tscan Therapeutics IncTCRX | 8 | Buy | $6.00 | +502.41% | Maintains | 3 months ago |
Celcuity IncCELC | 21 | Buy | $70.00 | -36.94% | Reiterates | 3 months ago |
Taysha Gene Therapies IncTSHA | 31 | Buy | $10.00 | +111.86% | Reiterates | 4 months ago |
Artiva Biotherapeutics IncARTV | 7 | Buy | $18.00 | +334.78% | Reiterates | 4 months ago |
Amicus Therapeutics IncFOLD | 2 | Buy | $14.00 | -1.96% | Upgrades | 5 months ago |
Recursion Pharmaceuticals IncRXRX | 25 | Buy | $8.00 | +95.12% | Reiterates | 5 months ago |
Novabridge BiosciencesNBP | 17 | Buy | $6.00 | +72.41% | Reiterates | 5 months ago |
Generation Bio CoGBIO | 18 | Buy | $15.00 | +163.16% | Reiterates | 6 months ago |
Nkarta IncNKTX | 17 | Buy | $10.00 | +350.45% | Reiterates | 6 months ago |
Sarepta Therapeutics IncSRPT | 33 | Hold | $50.00 | +146.55% | Downgrades | 7 months ago |
Rocket Pharmaceuticals IncRCKT | 21 | Hold | $42.00 | +1,113.87% | Downgrades | 8 months ago |
Immunocore Holdings PLCIMCR | 14 | Buy | $71.00 | +121.39% | Reiterates | 10 months ago |
Shattuck Labs IncSTTK | 13 | Hold | $8.00 | N/A | Downgrades | a year ago |
Nextcure IncNXTC | 9 | Buy | $48.00 | N/A | Reiterates | 2 years ago |
G1 Therapeutics IncGTHX | 17 | Buy | $6.00 | N/A | Maintains | 2 years ago |
Gamida Cell LtdGMDAQ | 8 | Buy | $6.00 | N/A | Reiterates | 2 years ago |
Cti Biopharma CorpCTIC | 5 | Buy | $9.00 | N/A | Reiterates | 3 years ago |
Tectonic Therapeutic IncTECX | 4 | Buy | $72.00 | N/A | Reiterates | 3 years ago |
Fate Therapeutics IncFATE | 1 | Hold | N/A | N/A | Initiates Coverage On | 4 years ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $225.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.